Skip to main content

Table 2 Patient and tumor characteristics in patients tested for HRG

From: Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Characteristic HRG-negative (n = 18) HRG-positive (n = 14)
Age at study entry (years) 61.6 (15.0) 56.3 (10.1)
BMI (kg/m2) 25.6 (4.3) 24.9 (4.2)
Time from diagnosis to metastasis (years) 5.6 (5.8) 3.8 (4.4)
Tumor grade
 1 2 (11.8) 2 (18.2)
 2 11 (64.7) 7 (63.6)
 3 4 (23.5) 2 (18.2)
ECOG score
 0 13 (76.5) 11 (84.6)
 1 4 (23.5) 2 (15.4)
 2+ 0 (0.0) 0 (0.0)
Concomitant diseases
 0 or 1 8 (44.4) 10 (76.9)
 2 to 4 10 (55.6) 2 (15.4)
 5+ 0 (0.0) 1 (7.7)
Metastasis pattern
 Brain 0 (0.0) 1 (7.1)
 Visceral 4 (22.2) 9 (64.3)
 Bone 2 (11.1) 1 (7.1)
 Other 12 (66.7) 3 (21.4)
Ever received chemotherapy
 No 18 (100.0) 14 (100.0)
 Yes 0 (0.0) 0 (0.0)
Ever received endocrine therapy
 No 1 (5.6) 1 (7.1)
 Yes 17 (94.4) 13 (92.9)
Ever received fulvestrant
 No 18 (100.0) 14 (100.0)
 Yes 0 (0.0) 0 (0.0)
Previous CDK4/6i documented
 No 0 (0.0) 1 (7.1)a
 Yes 18 (100.0) 13 (92.9)
SHERBOC line
 1 17 (94.4) 12 (85.7)
 2 1 (5.6) 2 (14.3)
  1. BMI Body mass index; ECOG Eastern Cooperative Oncology Group; HRG Heregulin. CDK4/6i CDK4/6 inhibitor
  2. Means and standard deviation (SD) are shown for continuous characteristics, and frequency and percentage for categorical characteristics
  3. a This patient was confirmed to be clinically eligible for SHERBOC despite CDK4/6i was not documented yet at time of database closure